This open-label randomized study compares the safety and efficacy of four ascending doses of PEG-interferon a-2a given once a week with a standard thrice weekly regimen of Roferon-A in non-cirrhotic patients with chronic hepatitis C. Endpoints for evaluation of efficacy will be normalization of ALT and disappearance of detectable HCV RNA from the serum.
Showing the most recent 10 out of 871 publications